Therapeutic drug monitoring and CYP2C19 genotyping guide the application of voriconazole in children.

ABSTRACT:

Background

This study used therapeutic drug monitoring (TDM) and CYP2C19 gene polymorphism analysis to explore the efficacy and safety of different doses of voriconazole (VCZ) for the clinical treatment of pediatric patients, with the aim of providing guidelines for individualized antifungal therapy in children.

Methods

Our study enrolled 94 children with 253 VCZ concentrations. The genotyping of CYP2C19 was performed by polymerase chain reaction (PCR)-pyrosequencing. VCZ trough concentration (C_trough) was detected by high-performance liquid chromatography-tandem mass spectrometry. SPSS 23.0 was used to analyze the correlations between VCZ concentration, CYP2C19 phenotype, adverse effects (AEs), and drug-drug interactions.

Results

A tot

SUBMITTER: Chen X 

PROVIDER: S-EPMC9442201 | biostudies-literature | 2022 Aug

REPOSITORIES: biostudies-literature